INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes
1. INMB stock surged 74.68% with high trading volume. 2. Company to present Phase 2 MINDFuL trial data on June 30. 3. XPro shows promising potential in treating Alzheimer's disease. 4. Trial overenrolled with 208 patients categorized as mild AD and MCI. 5. Strong correlation found between EMACC and CDR-SB in Alzheimer's assessment.